Stock HCM HUTCHMED (CHINA) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Pharmaceuticals

Delayed London S.E.
Other stock markets
 03:39:27 2024-04-26 am EDT 		5-day change 1st Jan Change
311.6 GBX +2.50% Intraday chart for HUTCHMED (China) Limited +15.41% +10.11%
Apr. 05 Hutchmed to Present New Data at US Cancer Research Conference MT
Apr. 05 HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024 CI

Business Summary

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Number of employees: 1,988

Sales per Business

HKD in Million2022Weight2023Weight Delta
Oncology/Immunology - Research and Development
43.5 %
307 9.2 % 2,853 43.5 % +829.49%
Other Ventures
36.9 %
2,056 61.6 % 2,422 36.9 % +17.81%
Oncology/Immunology - Marketed Products
19.6 %
976 29.2 % 1,285 19.6 % +31.68%

Sales per region

HKD in Million2022Weight2023Weight Delta
China
57.9 %
3,339 100.0 % 3,796 57.9 % +13.69%
United States and Others
42.1 %
0 0.0 % 2,764 42.1 % -

Managers

Managers TitleAgeSince
Wei Guo Su CEO
 Chief Executive Officer 66 04-12-31
Chig Fung Cheng DFI
 Director of Finance/CFO 57 08-06-30
Michael Shi CTO
 Chief Tech/Sci/R&D Officer 59 21-12-31
Karen Atkin COO
 Chief Operating Officer 58 20-12-31
Edith Shih BRD
 Director/Board Member 71 99-12-31
Mark Lee IRO
 Public Communications Contact 46 -
Selina Zhang HRO
 Human Resources Officer - 22-02-28
Yiling Cui LAW
 General Counsel - -
Charles Nixon LAW
 General Counsel 54 05-12-31
May Wang PRN
 Corporate Officer/Principal 60 09-12-31

Members of the board

Members of the board TitleAgeSince
Chi Keung To CHM
 Chairman 72 99-12-31
Graeme Jack BRD
 Director/Board Member 73 17-02-28
Dan Eldar BRD
 Director/Board Member 70 16-07-31
Edith Shih BRD
 Director/Board Member 71 99-12-31
Paul Carter BRD
 Director/Board Member 63 17-01-31
Chig Fung Cheng DFI
 Director of Finance/CFO 57 08-06-30
Wei Guo Su CEO
 Chief Executive Officer 66 04-12-31
Ling Yang BRD
 Director/Board Member 44 23-07-12
Shu Kam Mok BRD
 Director/Board Member 63 16-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 871,256,270 456,289,920 ( 52.37 %) 0 52.37 %

Shareholders

NameEquities%Valuation
CK HUTCHISON HOLDINGS LIMITED
38.16 %
332,478,770 38.16 % 1 136 M p
M&G Investment Management Ltd.
4.955 %
43,173,457 4.955 % 148 M p
Capital Research & Management Co. (Global Investors)
3.580 %
31,194,699 3.580 % 107 M p
Canada Pension Plan Investment Board
2.968 %
25,857,337 2.968 % 88 M p
EQT Private Capital Asia Ltd.
2.889 %
25,173,775 2.889 % 86 M p
Capital Research & Management Co. (International Investors)
1.504 %
13,102,356 1.504 % 45 M p
Capital International, Inc.
1.009 %
8,787,042 1.009 % 30 M p
Bank of China Investment Management Co., Ltd.
0.9980 %
8,695,000 0.9980 % 30 M p
Huatai-PineBridge Fund Management Co., Ltd.
0.5813 %
5,064,500 0.5813 % 17 M p
Penghua Fund Management Co., Ltd.
0.5467 %
4,763,000 0.5467 % 16 M p
NameEquities%Valuation
Schroder Investment Management (Hong Kong) Ltd.
2.399 %
4,179,836 2.399 % 70 M p
General Atlantic LLC
2.296 %
4,000,000 2.296 % 67 M p
Allianz Global Investors Asia Pacific Ltd.
0.8937 %
1,557,320 0.8937 % 26 M p
Bellevue Asset Management AG
0.6491 %
1,131,111 0.6491 % 19 M p
Slater Investments Ltd.
0.4616 %
804,350 0.4616 % 14 M p
Jane Street Group LLC
0.2988 %
520,712 0.2988 % 9 M p
Acadian Asset Management LLC
0.2806 %
488,913 0.2806 % 8 M p
Goldman Sachs International
0.2728 %
475,370 0.2728 % 8 M p
Millennium Management LLC
0.2249 %
391,856 0.2249 % 7 M p
AIA Investment Management Pte Ltd.
0.2245 %
391,278 0.2245 % 7 M p

Company contact information

HUTCHMED (China) Ltd.

Cheung Kong Center 2 Queen's Road Central

, Hong Kong

+852 2121 8200

http://www.hutch-med.com
address HUTCHMED (China) Limited(HCM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for HUTCHMED (China) Limited

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.798 USD
Average target price
5.412 USD
Spread / Average Target
+42.49%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HUTCHMED (CHINA) LIMITED Stock HUTCHMED (China) Limited
+10.11% 3.24B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.00% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.90% 331B
ABBVIE INC. Stock AbbVie Inc.
+7.95% 296B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.45% 233B
NOVARTIS AG Stock Novartis AG
+5.59% 201B
ROCHE HOLDING AG Stock Roche Holding AG
-10.22% 193B
PFIZER, INC. Stock Pfizer, Inc.
-12.26% 143B
AMGEN INC. Stock Amgen Inc.
-6.47% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. HCM Stock
  4. Company HUTCHMED (China) Limited